BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces Changes to Board of Directors and a Private Placement Offering
Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony will be joining the BriaCell board of directors Both additions have extensive experience in the biopharma industry, bringing expert knowledge in the field of clinical oncology Company recently announced a private placement offering that will generate proceeds for the phase IIa combination clinical trial of Bria-IMT with KEYTRUDA in advanced breast cancer BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, announced several key changes to its board of directors on March 18, 2019, as part of the company’s drive…